Inman Jager Wealth Management LLC Acquires 12,095 Shares of Pfizer Inc. (NYSE:PFE)

Inman Jager Wealth Management LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 52.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 34,960 shares of the biopharmaceutical company's stock after purchasing an additional 12,095 shares during the period. Inman Jager Wealth Management LLC's holdings in Pfizer were worth $886,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at $26,000. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer in the fourth quarter worth approximately $27,000. Gould Capital LLC lifted its position in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer in the 4th quarter valued at approximately $30,000. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. UBS Group boosted their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Stock Performance

Shares of NYSE:PFE traded up $0.04 during trading on Thursday, reaching $24.30. The stock had a trading volume of 31,721,433 shares, compared to its average volume of 41,253,048. The stock has a fifty day simple moving average of $23.38 and a two-hundred day simple moving average of $24.87. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The firm has a market capitalization of $138.18 billion, a price-to-earnings ratio of 17.61, a P/E/G ratio of 0.88 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter last year, the firm posted $0.82 EPS. The business's quarterly revenue was down 7.8% on a year-over-year basis. As a group, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.08%. Pfizer's dividend payout ratio is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.